Milestone Pharmaceuticals Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications.. The company’s lead product investigational candidate, etripamil (MSP-2017), is entering Phase 3 development. Etripamil is a new, potent, short-acting, investigational calcium channel blocker being developed as a rapid-onset nasal spray that can be self-administered to terminate paroxysmal supraventricular tachycardia (PSVT) episodes.
Featured News & Events
Milestone Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference
Milestone Pharmaceuticals USA, Inc. today announced that Joseph G. Oliveto, President and Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 27, 2018 at 9:50 a.m. Eastern Time.